Introduction: Getting the basics right Oxford BioDynamics’ (OBD) EpiSwitch™ biomarker discovery platform combined with their newly enhanced detection technology gives the company valuable quantitative insights into chromosome conformations (DNA protein
Oxford BioDynamics’ EpiSwitch™ technology is based on epigenetics, mechanisms that alter gene expression without altering the underlying DNA sequence and whose deregulation plays a role in the development of cancer,
The long-running study on aging and brain health at the University of Kentucky’s Sanders-Brown Center on Aging (SBCoA) Alzheimer’s Disease Center has once again resulted in important new findings –
Today the Government has announced changes to guidance in England for people shielding from COVID-19. These changes will be introduced in two stages – from 6 July and 1 August.
Mutations in the UBQLN2 gene, known to cause amyotrophic lateral sclerosis (ALS), promote the buildup of toxic waste in brain cells by preventing the normal function of two cellular degradation mechanisms, a study has found.
Oxford BioDynamics Plc (LON:OBD), a biotechnology company focused on the discovery and development of epigenetic biomarkers, based on regulatory 3D genome architecture, using its liquid biopsy platform EpiSwitch™, has announced its
The Black Women’s Health Imperative (BWHI) recently created a Rare Disease Diversity Coalition focused on reducing racial disparities in the rare disease community. Getting a timely and accurate diagnosis for a disease
Oxford BioDynamics Plc (LON:OBD), a biotechnology company focused on the discovery and development of epigenetic biomarkers, based on regulatory 3D genome architecture, using its liquid biopsy platform EpiSwitchä, announced that Dr
The coronavirus is known with certainty that it emerged in China in November and has since spread to almost the entire world, where it has infected more than 5 million people and killed
Oxford BioDynamics’ EpiSwitch technology has been chosen as the biomarker platform for prognostic and predictive profiling of COVID-19 patients in the GETAFIX clinical study.Institute of Infection, Immunity and Inflammation, University
© 2023 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
